CytoMed Therapeutics (NASDAQ: GDTC) denies false claims, reaffirms progress in cancer treatment research in Singapore.
Singapore-based CytoMed Therapeutics Limited (NASDAQ: GDTC) is a clinical stage biopharmaceutical company that specializes in developing affordable donor-derived cell-based immunotherapies for various cancers. The company released a statement in response to recent false claims about its research programs, clinical advancements, and overall operations. This initiative aims to clarify misinformation circulating about CytoMed's work in advancing treatments for a wide spectrum of cancers, encompassing both blood-related and solid tumors.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments